Abstract
ZBTB7 was recently recognized as a proto-oncogene. We studied its prognostic value and relationship to clinicopathological variables in 125 breast cancer patients. ZBTB7 expression was significantly higher in breast cancer tissues than in normal breast tissues, but its gene amplification copies were relatively low. ZBTB7 expression levels were significantly correlated with histological grade (p = .023) and marginally inversely correlated with the presence of estrogen receptors (p = .053); its overexpression significantly predicted shorter recurrence-free survival (p = .033). Our results showed that ZBTB7 might be implicated in breast cancer development and may serve as a promising prognostic marker.
MeSH terms
-
Biomarkers, Tumor / analysis*
-
Biomarkers, Tumor / genetics
-
Blotting, Western
-
Breast Neoplasms / chemistry*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy
-
Chi-Square Distribution
-
DNA-Binding Proteins / analysis*
-
DNA-Binding Proteins / genetics
-
Disease-Free Survival
-
Female
-
Gene Amplification
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Immunohistochemistry
-
Kaplan-Meier Estimate
-
Neoplasm Staging
-
Polymerase Chain Reaction
-
Proto-Oncogene Mas
-
Receptors, Estrogen / analysis
-
Recurrence
-
Risk Assessment
-
Time Factors
-
Transcription Factors / analysis*
-
Transcription Factors / genetics
-
Treatment Outcome
-
Up-Regulation
Substances
-
Biomarkers, Tumor
-
DNA-Binding Proteins
-
MAS1 protein, human
-
Proto-Oncogene Mas
-
Receptors, Estrogen
-
Transcription Factors
-
ZBTB7A protein, human